Sen. Snowe (R-Vt.) introduces bill (S 1177) July 12 that would give HHS authority to grant Medicaid demonstration project waivers like those given to Maine and Vermont, in which Medicaid drug prices are offered to residents without drug coverage. The Pharmaceutical Research & Manufacturers of America won its case against the Vermont program in Washington, D.C. federal appeals court and has filed a lawsuit against the Maine program (1"The Pink Sheet" July 9, p. 3). Sens. Collins (R-Maine), Jeffords (I-Vt.) and Leahy (D-Vt.) co-sponsored the bill
You may also be interested in...
The Maine Rx Program will be prevented from going into effect until the end of July as the Pharmaceutical Research & Manufacturers of America considers whether it should pursue its case against the program to the U.S. Supreme Court.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials